List of Excipients in Branded Drug DICLOFENAC SODIUM TOPICAL GEL, 1%

Generic Drugs Containing DICLOFENAC SODIUM TOPICAL GEL, 1%

Company	Ingredient	NDC	Excipient
Mohnark Pharmaceuticals Inc	diclofenac sodium topical gel, 1% (nsaid)	73715-005	AMMONIA
Mohnark Pharmaceuticals Inc	diclofenac sodium topical gel, 1% (nsaid)	73715-005	COCO-CAPRYLATE/CAPRATE
Mohnark Pharmaceuticals Inc	diclofenac sodium topical gel, 1% (nsaid)	73715-005	MINERAL OIL
Mohnark Pharmaceuticals Inc	diclofenac sodium topical gel, 1% (nsaid)	73715-005	PROPYLENE GLYCOL
Mohnark Pharmaceuticals Inc	diclofenac sodium topical gel, 1% (nsaid)	73715-005	WATER

What are the Most Frequently-Used Excipients in DICLOFENAC SODIUM TOPICAL GEL, 1%?

# Of NDCs	Excipient
1	AMMONIA
1	COCO-CAPRYLATE/CAPRATE
1	MINERAL OIL
1	PROPYLENE GLYCOL
1	WATER

Diclofenac Sodium Topical Gel 1%: Excipient Strategy, Patent Exposure, and Commercial Opportunities

Last updated: August 13, 2026

Diclofenac sodium topical gel 1% is a mature, highly competitive topical NSAID market with limited active-ingredient differentiation. Commercial value depends on formulation performance, manufacturing efficiency, sensory properties, retail positioning, and regulatory execution. The strongest opportunities are lower-cost generic supply, improved spreadability and drying, packaging innovation, pediatric or special-population positioning where permitted, and regional products adapted to local regulatory pathways.

What is diclofenac sodium topical gel 1%?

Diclofenac sodium topical gel 1% is a nonsteroidal anti-inflammatory drug applied to the skin for localized treatment of osteoarthritis pain. The reference product in the United States is Voltaren Gel, originally approved by the FDA in 2007 under NDA 022122. The product contains diclofenac sodium at 1% w/w and uses a hydroalcoholic, carbomer-based gel system.[1]

The U.S. market includes:

Product category	Regulatory route	Primary commercial use
Voltaren Gel 1%	Prescription NDA	Osteoarthritis pain
Generic diclofenac sodium topical gel 1%	ANDA	Prescription substitution
Voltaren Arthritis Pain	OTC NDA	Temporary relief of arthritis pain
Regional diclofenac gels	National or decentralized pathways	Prescription or OTC use, depending on jurisdiction

The OTC product is marketed in the United States by Haleon following the consumer-health business transition from GSK.[2] The prescription and OTC products may share the active pharmaceutical ingredient and broad dosage form but are not necessarily identical in excipient composition, packaging, labeling, or commercial positioning.

What excipients are used in diclofenac sodium topical gel 1%?

The reference Voltaren Gel formulation uses excipients that support drug solubilization, skin application, evaporation, viscosity, and product stability.

Excipient or excipient class	Function in the formulation	Commercial significance
Carbomer homopolymer type C	Gel formation and viscosity control	Controls rheology, suspension behavior, and skin residence
Propylene glycol	Cosolvent and humectant	Supports diclofenac solubilization and skin feel
Isopropyl alcohol	Volatile solvent and penetration-supporting component	Promotes quick drying and cooling sensation
Mineral oil	Emollient and sensory modifier	Reduces excessive tack and improves after-feel
Polyoxyl 20 cetostearyl ether	Surfactant and emulsification aid	Supports physical uniformity
Cocoyl caprylocaprate	Emollient and solvent component	Modifies spreadability and skin feel
Purified water	Main vehicle	Controls the hydroalcoholic matrix
Ammonia	Neutralizing agent and pH adjuster	Activates carbomer thickening and controls pH

The specific inactive-ingredient profile is documented in the FDA-approved labeling for Voltaren Gel.[1] A generic formulation does not need to duplicate every excipient, but it must meet applicable requirements for safety, quality, bioequivalence, and product performance.

How should excipients be selected for diclofenac gel?

Excipient selection should begin with the target product profile rather than with ingredient substitution. The key attributes are drug solubility, viscosity, pH, spreadability, drying time, skin tolerability, drug release, permeation, microbial quality, and package compatibility.

Solvent and cosolvent system

Diclofenac sodium is highly water-soluble relative to diclofenac free acid, but the formulation still requires control of solvent balance. Propylene glycol can improve solubilization and hydration, while isopropyl alcohol reduces drying time and contributes to the consumer-perceived cooling effect.

A higher alcohol content may improve dry-down but can increase stinging, dryness, and flammability concerns. A higher propylene glycol content may improve moisturization but can increase tackiness and prolong drying. The commercial target is usually a fast-drying gel that leaves limited residue without causing unacceptable skin irritation.

Carbomer and rheology modifiers

Carbomer is central to the product’s application profile. Its concentration, grade, neutralization level, and hydration process determine:

• Yield stress
• Extrudability from the tube
• Vertical hold on the skin
• Spreadability
• Drug release
• Shear recovery
• Long-term viscosity stability

A formulation that is too thin may run from the application site and reduce dose uniformity. A formulation that is too viscous may be difficult to spread and may leave a visible film. Carbomer grade changes can therefore affect both consumer preference and bioequivalence risk.

Alternative rheology modifiers, including cellulose derivatives or acrylate copolymers, may create a differentiated texture. They also introduce greater development risk because changes in polymer chemistry can alter drug release and skin permeation.

Neutralization and pH control

Ammonia or another suitable base neutralizes carbomer and controls gel structure. pH affects:

• Carbomer viscosity
• Diclofenac ionization
• Skin tolerability
• Preservative performance
• Chemical stability
• Permeation behavior

The development objective is not simply maximum viscosity. A narrow pH and rheology control strategy is needed to maintain lot-to-lot performance.

Emollients and sensory modifiers

Mineral oil, ester emollients, and related oil-phase components can reduce the dry, tight feel associated with hydroalcoholic gels. Cocoyl caprylocaprate is useful where the developer wants improved glide and a less sticky residue.

Sensory differentiation has direct commercial value in a mature OTC market. Consumers commonly compare topical analgesics by drying time, odor, residue, ease of washing, and comfort during repeated use. A formulation with similar pharmacologic performance but better sensory characteristics can support premium positioning if the product claims and regulatory evidence remain appropriate.

What formulation patents protect diclofenac sodium topical gel 1%?

The main patent opportunity is not broad ownership of diclofenac. Diclofenac is an established active ingredient, and the basic 1% topical gel concept has extensive prior art. Relevant formulation protection typically focuses on:

• Specific solvent systems
• Carbomer grades and concentration ranges
• pH and neutralization ranges
• Penetration-enhancing excipients
• Drug release profiles
• Skin permeation characteristics
• Reduced irritation
• Improved stability
• Packaging and dispensing systems
• Manufacturing processes

The U.S. reference product’s Orange Book record should be reviewed for listed patents and regulatory exclusivity associated with NDA 022122.[3] Patent protection for a mature topical product may not align with the practical barriers faced by a generic developer. A listed formulation patent can be challenged, designed around, licensed, or rendered commercially less important by the availability of other approved products.

A new formulation patent is strongest when it claims a measurable technical result, such as a defined release profile, improved stability under accelerated conditions, lower irritation, or a reproducible manufacturing process. Claims based only on routine excipient substitutions face greater validity and obviousness risk.

When does diclofenac sodium topical gel lose exclusivity?

The principal U.S. market exclusivity for the original Voltaren Gel product has expired, and generic diclofenac sodium topical gel 1% products are available through the ANDA pathway. The OTC Voltaren product has a separate approval and commercial channel, but OTC status does not create a new monopoly over diclofenac sodium gel as a dosage form.

Exclusivity analysis must separate four elements:

Exclusivity element	Relevance to diclofenac gel
NCE exclusivity	Not relevant to this mature active ingredient
NDA exclusivity	Historically relevant to initial Voltaren Gel approval
Listed patents	May affect specific approved claims or formulations
OTC regulatory status	Supports consumer distribution but does not eliminate generic competition

A developer should assess the current Orange Book listing, FDA-approved labels, and litigation docket before selecting a launch strategy.[1,3] Patent expiry dates can differ by patent, jurisdiction, pediatric extensions, terminal disclaimers, and regulatory adjustments.

How does the FDA regulate generic diclofenac sodium gel?

Generic diclofenac sodium topical gel 1% is generally developed under section 505(j) of the Federal Food, Drug, and Cosmetic Act through an ANDA. The product must demonstrate pharmaceutical equivalence and bioequivalence to the reference listed drug, together with appropriate chemistry, manufacturing, and controls data.[4]

Topical products create a more complex bioequivalence problem than conventional immediate-release tablets. FDA evaluation can consider:

• Q1 sameness of inactive ingredients
• Q2 sameness of inactive-ingredient concentrations
• Q3 characterization of structural and physical attributes
• In vitro drug release
• In vitro permeation
• Comparative clinical endpoint studies where required
• Product rheology and viscosity
• pH and globule or particle size, if relevant
• Microbial limits and preservative performance

The FDA’s product-specific guidance for diclofenac sodium topical gel 1% is a central development document.[5] A formulation that departs from the reference product may reduce the probability of an efficient ANDA pathway, particularly if the change affects drug release or skin permeation.

What is the Orange Book status of Voltaren Gel?

Voltaren Gel is listed in the FDA Orange Book under NDA 022122.[3] The Orange Book identifies the reference listed drug and any relevant patent or exclusivity information reported by the NDA holder.

For commercial diligence, the record should be examined for:

1. Listed patents and their statutory expiration dates.
2. Paragraph IV certifications filed by ANDA applicants.
3. Thirty-month stays resulting from patent litigation.
4. Approved generic equivalents.
5. Whether a patent covers the drug substance, formulation, method of use, or another listed claim.

Because diclofenac sodium topical gel 1% has multiple approved and marketed versions, the relevant question is often whether a new product can obtain approval and compete against existing generics, rather than whether it can eliminate the reference product’s protection.

Which companies are challenging the Voltaren Gel market?

Competition comes from several groups:

• Large generic manufacturers with established topical manufacturing capacity.
• Specialty pharmaceutical companies focused on dermatology and pain products.
• OTC companies with retail distribution.
• Contract development and manufacturing organizations.
• Regional manufacturers selling diclofenac gels outside the United States.

The competitive advantage is usually operational. Tube-filling capacity, solvent handling, carbomer processing, stability control, and retail distribution can matter more than the active ingredient.

Paragraph IV litigation is possible where an ANDA applicant certifies that a listed patent is invalid, unenforceable, or not infringed. The commercial impact depends on the patent claims, filing date, litigation outcome, settlement terms, and whether other generic approvals are available.

What commercial opportunities exist in excipient design?

Lower-cost generic formulation

The most direct opportunity is a robust formulation that uses widely available excipients and minimizes processing complexity. Opportunities include:

• Reduced dependence on specialty emollients.
• Simplified solvent systems.
• Lower-cost tube and carton configurations.
• Shorter mixing and hydration cycles.
• Improved batch yield.
• Reduced solvent loss during manufacturing.

Cost savings must not compromise bioequivalence, stability, or sensory performance.

Premium OTC sensory positioning

A differentiated OTC product could focus on faster drying, reduced residue, low odor, improved spreadability, or a less greasy after-feel. These attributes may support a higher retail price, although the claims must remain consistent with the approved labeling and supporting data.

Pump and metered-dose packaging

A pump can improve hygiene and reduce direct contact with the product. A metered-dose pump may support dose consistency and reduce product waste. The development burden includes pump compatibility, priming behavior, dose delivery throughout container life, air exposure, and extractables and leachables.

Preservative and irritation reduction

A developer may evaluate preservative-free or low-preservative systems, particularly where the formulation’s water activity, packaging, and microbial controls permit. The commercial benefit is strongest when the product addresses skin sensitivity or repeated application.

Changes to alcohol, propylene glycol, fragrance, or surfactant levels may reduce irritation. Those changes can also alter drug permeation, making comparative performance testing essential.

Regional and emerging-market products

Diclofenac topical products are widely used outside the United States. Commercial opportunities may exist in markets where prescription and OTC classifications differ, provided the product meets local requirements for:

• Active-ingredient quality
• Local clinical or bioequivalence evidence
• Stability zones
• Labeling language
• Pharmacovigilance
• GMP compliance
• Import and manufacturing authorization

A formulation optimized for hot and humid climates may require stronger packaging, viscosity control, and stability protection than a product developed for temperate markets.

What manufacturing and intellectual-property barriers exist?

The primary manufacturing barriers are process control and scale-up. Carbomer hydration, neutralization, solvent addition, deaeration, and filling can produce significant batch variation if the order of addition and mixing energy are not tightly controlled.

Important control points include:

• Carbomer dispersion without fisheyes or agglomerates.
• Uniform diclofenac distribution.
• Controlled neutralization.
• Limited air incorporation.
• Alcohol retention and evaporation control.
• Tube compatibility.
• Viscosity and pH uniformity.
• Microbial control.
• Stability under temperature cycling.

The strongest defensible IP may be a process patent or formulation patent tied to reproducible performance. A developer can also protect trade secrets covering mixing order, processing temperature, deaeration, filling conditions, and in-process testing.

How strong is the patent estate for diclofenac sodium topical gel 1%?

The estate is commercially meaningful but difficult to treat as a single barrier. The active ingredient and general dosage form are mature. Remaining value is more likely to reside in specific formulations, use claims, packaging, manufacturing processes, or brand assets.

Estate component	Relative strategic value
Diclofenac sodium composition	Low for new entrants because of mature prior art
Basic 1% topical gel	Low to moderate
Defined excipient combinations	Moderate if linked to performance
Drug-release or permeation claims	Moderate to high if technically supported
Manufacturing process	Moderate, especially as a trade secret
OTC brand and retail presence	High commercial value but not patent exclusivity
Packaging and dispensing system	Moderate
Method-of-use claims	Variable and dependent on enforceability

A freedom-to-operate review should cover U.S., European, Canadian, Japanese, Australian, and major emerging-market rights. The analysis should include active patents, abandoned applications, continuations, divisional applications, and prosecution history.

What generic launch risks exist?

Generic launch risk is concentrated in five areas:

1. Bioequivalence failure caused by changes in viscosity, solvent balance, or drug release.
2. Manufacturing scale-up failure after successful laboratory development.
3. Price erosion from multiple approved ANDAs.
4. Patent litigation or settlement restrictions.
5. Retail displacement by the established OTC brand.

An early-filer strategy may offer greater market access but also increases Paragraph IV litigation exposure. A later filer may face lower patent risk but enter a heavily discounted market.

What licensing deals are relevant?

Licensing opportunities generally involve one of four assets:

• A differentiated topical formulation.
• A regional marketing authorization.
• A manufacturing platform.
• A retail or OTC distribution channel.

A formulation owner may license technology to a generic company with ANDA capability. A consumer-health company may license a product from a specialty manufacturer to obtain retail access. Deal value depends on exclusivity by territory, regulatory status, manufacturing transfer requirements, minimum purchase commitments, royalties, and responsibility for post-approval changes.

The most attractive licensing asset is usually an approved or near-approved product with validated manufacturing and a clear differentiation claim. Early formulation concepts generally command less value because the buyer bears bioequivalence and scale-up risk.

Key Takeaways

• Diclofenac sodium topical gel 1% is a mature, competitive product category.
• Excipient strategy should prioritize bioequivalence, skin tolerability, drying time, spreadability, and manufacturing robustness.
• Carbomer, propylene glycol, isopropyl alcohol, neutralizer, and emollients are the main formulation levers.
• The strongest formulation IP links a defined composition to measurable technical performance.
• Generic competition has reduced the value of basic dosage-form patents.
• Commercial opportunities remain in low-cost manufacturing, premium sensory performance, metered-dose packaging, regional products, and OTC distribution.
• The principal FDA development risk is failure to match the reference product’s critical quality and performance attributes.
• Patent diligence should focus on current Orange Book listings, Paragraph IV activity, litigation, settlements, and jurisdiction-specific formulation rights.

FAQs

Can a generic diclofenac gel use different excipients from Voltaren Gel?

Yes. The generic product may use different inactive ingredients if it satisfies FDA requirements for pharmaceutical equivalence, safety, bioequivalence, and product quality. Excipient changes that affect rheology, drug release, or skin permeation can increase development risk.

Is diclofenac sodium topical gel 1% suitable for an OTC product?

Yes. Voltaren Arthritis Pain is an FDA-approved OTC product for temporary relief of arthritis pain. An OTC sponsor must meet the applicable FDA labeling, safety, manufacturing, and approval requirements. Prescription-to-OTC status does not automatically transfer to a new product.

Which excipient has the greatest effect on diclofenac gel performance?

Carbomer often has the greatest effect on viscosity, spreadability, residence time, and release behavior. The solvent system and neutralization level are also major determinants of product performance.

Can a diclofenac gel patent block a generic launch after patent expiry?

A patent cannot block the covered product after valid patent expiry, but other patents, regulatory exclusivity, litigation stays, settlement agreements, or separate jurisdictional rights may affect launch timing. The current Orange Book and patent records control the assessment.

Is a fragrance-free diclofenac gel commercially attractive?

It can be attractive for consumers who dislike medicinal odor or have sensitive skin. The formulation must maintain stability, drug release, microbial quality, and regulatory compliance without relying on fragrance to mask the odor of the base or active product.

References

1. U.S. Food and Drug Administration. (2023). Voltaren Gel (diclofenac sodium topical gel), 1% prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/022122s017lbl.pdf

2. Haleon. (2023). Voltaren Arthritis Pain topical gel product information. https://www.voltaren.com/

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

4. U.S. Food and Drug Administration. (2024). Abbreviated new drug application process. https://www.fda.gov/drugs/types-applications/abbreviated-new-drug-application-anda

5. U.S. Food and Drug Administration. (2024). Product-specific guidances for generic drug development. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/product-specific-guidances-generic-drug-development